SAB Biotherapeutics IncNASDAQ:SABS
- LAST PRICE3.1300
- TODAY'S CHANGE (%)0.0600 (1.9544%)
- Bid / Lots3.0000/ 1
- Ask / Lots3.1300/ 1
- Open / Previous Close3.2200 / 3.0700
- Day Range
- 52 Week Range
- Volume28,433
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SABS |
|---|---|---|
| 09:32 ET | 1031 | 3.22 |
| 09:39 ET | 500 | 3.2094 |
| 09:48 ET | 575 | 3.19 |
| 09:50 ET | 100 | 3.18 |
| 10:06 ET | 100 | 3.1129 |
| 10:09 ET | 467 | 3.1684 |
| 10:11 ET | 519 | 3.16 |
| 10:15 ET | 200 | 3.1 |
| 10:22 ET | 2500 | 3.09 |
| 10:24 ET | 3500 | 3.03 |
| 10:31 ET | 365 | 3 |
| 10:33 ET | 194 | 3.132 |
| 10:49 ET | 100 | 3.06 |
| 10:56 ET | 200 | 3 |
| 11:14 ET | 200 | 3 |
| 11:32 ET | 280 | 3.08 |
| 11:34 ET | 200 | 3.01 |
| 11:59 ET | 459 | 3.07 |
| 12:01 ET | 100 | 3.07 |
| 12:08 ET | 200 | 3.045 |
| 12:55 ET | 200 | 3.02 |
| 01:11 ET | 2400 | 3.11 |
| 01:22 ET | 200 | 3.02 |
| 01:58 ET | 200 | 3.02 |
| 02:05 ET | 400 | 3.1303 |
| 02:25 ET | 115 | 3.03 |
| 02:39 ET | 550 | 3.028 |
| 02:48 ET | 394 | 3.02 |
| 02:56 ET | 501 | 3.02 |
| 02:57 ET | 374 | 3.01 |
| 03:17 ET | 1393 | 3.0487 |
| 03:21 ET | 700 | 3.045 |
| 03:24 ET | 100 | 3.07 |
| 03:26 ET | 100 | 3.07 |
| 03:28 ET | 100 | 3.08 |
| 03:32 ET | 100 | 3.07 |
| 03:33 ET | 200 | 3.07 |
| 03:37 ET | 100 | 3.09 |
| 03:39 ET | 100 | 3.09 |
| 03:42 ET | 181 | 3.1 |
| 03:44 ET | 200 | 3.12 |
| 03:46 ET | 500 | 3.11 |
| 03:48 ET | 200 | 3.12 |
| 03:50 ET | 100 | 3.13 |
| 03:51 ET | 700 | 3.13 |
| 03:53 ET | 200 | 3.13 |
| 03:57 ET | 281 | 3.13 |
| 04:00 ET | 1246 | 3.13 |
Nov 7, 2024
DJ SAB Biotherapeutics Is Maintained at Buy by Chardan Capital, from 9:22AM ET on Thursday Nov 07, 2024 by Dow Jones
9:22AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
*DJ SAB Biotherapeutics 3Q Loss/Shr $1.12 >SABS, from 5:18PM ET on Wednesday Nov 06, 2024 by Dow Jones
5:18PM ET on Wednesday Nov 06, 2024 by Dow JonesSAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update, from 5:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
5:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
Oct 31, 2024
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference, from 7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
SAB Biotherapeutics Inc | 28.9M | -0.5x | --- |
Lipocine Inc | 27.5M | -6.8x | --- |
IGC Pharma Inc | 27.6M | -1.9x | --- |
HCW Biologics Inc | 32.3M | -0.8x | --- |
Marker Therapeutics Inc | 27.7M | -2.9x | --- |
Lumos Pharma Inc | 37.3M | -1.0x | --- |
Company Information
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
Contact Information
- Headquarters
- 777 W 41St St, Suite 401MIAMI BEACH, FL, United States 33140
- Phone
- 305-845-2813
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board, Chief Executive Officer
- Samuel Reich
- President, Director
- Eddie Sullivan
- Non-Executive Independent Vice Chairman of the Board
- David Link
- Chief Financial Officer
- Lucy To
- Chief Operating Officer
- Christoph Bausch
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.9M |
|---|---|
Revenue (TTM) | $1.5M |
Shares Outstanding | 9.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.63 |
EPS | $-5.84 |
Book Value | $6.21 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 19.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,422.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
